


## Lercanidipine-<sup>13</sup>C,<sub>3</sub>D hydrochloride

<b>Cat. No.:</b>	HY-B0612AS
<b>CAS No.:</b>	1261397-71-0
<b>Molecular Formula:</b>	C <sub>35</sub> <sup>13</sup> CH <sub>39</sub> D <sub>3</sub> ClN <sub>3</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	652.2
<b>Target:</b>	Calcium Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Lercanidipine- <sup>13</sup> C, <sub>3</sub> D <sub>3</sub> (hydrochloride) is the deuterium and <sup>13</sup> C labeled Lercanidipine hydrochloride[1]. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[2][3][4].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.
- [2]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. *Int J Clin Pract*, 2006. 60(11): p. 1364-70.
- [3]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? *Expert Opin Drug Metab Toxicol*, 2009. 5(8): p. 981-7.
- [4]. Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. *J Pharmacol Pharmacother.* Oct-Dec 2017(4):155-165.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA